Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Oncostatin M’s Involvement in the Pathogenesis of Chronic Rhinosinusitis: Focus on Type 1 and 2 Inflammation

Chie Ishikawa
,
Sachio Takeno
* ORCID logo ,
Yukako Okamoto
,
Tomohiro Kawasumi
,
Takashi Kakimoto
,
Kota Takemoto
ORCID logo ,
Manabu Nishida
,
Takashi Ishino
ORCID logo ,
Takao Hamamoto
ORCID logo ,
Tsutomu Ueda
,
Akio Tanaka
Version 1 : Received: 16 October 2023 / Approved: 16 October 2023 / Online: 17 October 2023 (08:05:36 CEST)

A peer-reviewed article of this Preprint also exists.

Ishikawa, C.; Takeno, S.; Okamoto, Y.; Kawasumi, T.; Kakimoto, T.; Takemoto, K.; Nishida, M.; Ishino, T.; Hamamoto, T.; Ueda, T.; Tanaka, A. Oncostatin M’s Involvement in the Pathogenesis of Chronic Rhinosinusitis: Focus on Type 1 and 2 Inflammation. Biomedicines 2023, 11, 3224. Ishikawa, C.; Takeno, S.; Okamoto, Y.; Kawasumi, T.; Kakimoto, T.; Takemoto, K.; Nishida, M.; Ishino, T.; Hamamoto, T.; Ueda, T.; Tanaka, A. Oncostatin M’s Involvement in the Pathogenesis of Chronic Rhinosinusitis: Focus on Type 1 and 2 Inflammation. Biomedicines 2023, 11, 3224.

Abstract

ABSTRACT: Objectives: Oncostatin M (OSM), a member of the interleukin (IL)-6 family of cytokines, is known to elicit pathogenic effects involving disruption of the epithelial barrier function as a part of immunological response networks. It is not yet known how these integrated cytokine signals influence inflammation and other physiological processes in the pathology of chronic rhinosinusitis (CRS). We investigated the expression and distribution of OSM and OSM receptor (OSMR) in sinonasal specimens of CRS patients, and we compared the results with a panel of inflammatory cytokine levels and clinical features. Materials and Methods: We classified CRS patients as eosinophilic (ECRS, n=36) or non-eosinophilic (non-ECRS, n=35) based on the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (JESREC) phenotypic criteria, and we compared their cases with those of 68 non-CRS subjects. We also examined stimulatory effects of OSM on the expression levels of cytokine receptors by using the human bronchial epithelium cell line BEAS-2B. Results: An RT-PCR showed that the OSM mRNA levels were significantly increased in the ethmoid sinus mucosa of the CRS patients. The OSM mRNA levels were positively correlated with those of TNF-α, IL-1β, IL-13, and OSMR-β. In BEAS-2B cells, OSM treatment induced significant increases in the OSMR-β, IL-1R1, and IL-13Ra mRNA levels. Conclusions: Our findings indicate that OSM is involved in the pathogenesis of CRS in both type 1 and type 2 inflammation, suggesting the OSM signaling pathway as a potential therapeutic target for modulating epithelial stromal interactions.

Keywords

paranasal sinus; chronic rhinosinusitis; CRS; epithelial cell; eosinophil; oncostatin M; OSM; OSM receptor; OSMR

Subject

Medicine and Pharmacology, Otolaryngology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.